CTMX vs. XERS
CTMX (CytomX Therapeutics, Inc.) and XERS (Xeris Biopharma Holdings, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, CTMX returned -10.54%/yr vs 21.35%/yr for XERS. Their 0.30 correlation means their historical movements had little consistent relationship.
Performance
CTMX vs. XERS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CTMX achieves a -27.23% return, which is significantly lower than XERS's 2.93% return.
CTMX
- 1D
- -5.49%
- 1M
- -18.85%
- 6M
- -45.52%
- YTD
- -27.23%
- 1Y
- 31.91%
- 3Y*
- 22.41%
- 5Y*
- -10.54%
- 10Y*
- -11.18%
- ALL TIME*
- -14.08%
XERS
- 1D
- -4.04%
- 1M
- -2.42%
- 6M
- 9.78%
- YTD
- 2.93%
- 1Y
- 50.19%
- 3Y*
- 44.28%
- 5Y*
- 21.35%
- 10Y*
- —
- ALL TIME*
- -7.90%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $9.26M | $11.79M | $14.34M | |
| $11.42M | $15.11M | $13.85M |
CTMX vs. XERS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
CTMX CytomX Therapeutics, Inc. | -27.23% | 313.59% | -33.55% | -3.13% | -63.05% | -33.89% | -21.18% | -44.97% | -41.20% |
XERS Xeris Biopharma Holdings, Inc. | 2.93% | 131.56% | 44.26% | 76.69% | -54.61% | -40.45% | -30.21% | -58.53% | 7.94% |
Correlation
The correlation between CTMX and XERS is 0.24, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.24 |
Correlation (3Y) Balances recent behavior with more history. | 0.31 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.32 |
Correlation (All Time) Calculated using the full available price history since Jun 21, 2018 | 0.30 |
Fundamentals
CTMX:
$498.55M
XERS:
$1.39B
CTMX:
-$0.35
XERS:
$0.07
CTMX:
14.90
XERS:
4.58
CTMX:
1.72
XERS:
110.31
CTMX:
$35.54M
XERS:
$314.85M
CTMX:
$24.77M
XERS:
$187.04M
CTMX:
-$62.07M
XERS:
$41.72M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CTMX vs. XERS — Risk / Return Rank
CTMX
XERS
CTMX vs. XERS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for CytomX Therapeutics, Inc. (CTMX) and Xeris Biopharma Holdings, Inc. (XERS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CTMX | XERS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.62 | ||
| Sortino ratioReturn per unit of downside risk | -0.28 | ||
| Omega ratioGain probability vs. loss probability | 1.18 | 1.23 | -0.06 |
| Calmar ratioReturn relative to maximum drawdown | 0.73 | 1.27 | -0.53 |
| Martin ratioReturn relative to average drawdown | 1.48 | 2.17 | -0.69 |
Loading charts...
Drawdowns
CTMX vs. XERS - Drawdown Comparison
The maximum CTMX drawdown since its inception was -98.74%, roughly equal to the maximum XERS drawdown of -96.22%. Use the drawdown chart below to compare losses from any high point for CTMX and XERS.
Loading charts...
Drawdown Indicators
| CTMX | XERS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.74% | -96.22% | -2.52% |
Max Drawdown (1Y)Largest decline over 1 year | -56.89% | -46.57% | -10.32% |
Max Drawdown (3Y)Largest decline over 3 years | -91.59% | -47.20% | -44.39% |
Max Drawdown (5Y)Largest decline over 5 years | -94.16% | -64.85% | -29.31% |
Max Drawdown (10Y)Largest decline over 10 years | -98.74% | — | — |
Current DrawdownCurrent decline from peak | -90.94% | -70.33% | -20.61% |
Average DrawdownAverage peak-to-trough decline | -71.12% | -78.86% | +7.74% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 28.20% | 27.13% | +1.07% |
Volatility
CTMX vs. XERS - Volatility Comparison
The current volatility for CytomX Therapeutics, Inc. (CTMX) is 12.32%, while Xeris Biopharma Holdings, Inc. (XERS) has a volatility of 13.14%. This indicates that CTMX experiences smaller price fluctuations and is considered to be less risky than XERS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CTMX | XERS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.32% | 13.14% | -0.82% |
Volatility (6M)Calculated over the trailing 6-month period | 62.08% | 30.94% | +31.14% |
Volatility (1Y)Calculated over the trailing 1-year period | 93.85% | 55.25% | +38.60% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 141.95% | 67.85% | +74.10% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 111.36% | 79.23% | +32.13% |
Dividends
CTMX vs. XERS - Dividend Comparison
Neither CTMX nor XERS has paid dividends to shareholders.
Financials
CTMX vs. XERS - Financials Comparison
This section allows you to compare key financial metrics between CytomX Therapeutics, Inc. and Xeris Biopharma Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CTMX and XERS have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
XERS has higher volatility (13.14%) compared to CTMX (12.32%). In terms of maximum drawdown, CTMX dropped -98.74% vs XERS's -96.22%.
XERS currently has the higher Sharpe Ratio (1.07 vs 0.45), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CTMX and XERS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer